<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204321</url>
  </required_header>
  <id_info>
    <org_study_id>Hausberg_Lang-Sir/MMF</org_study_id>
    <secondary_id>EKF Hausberg Lang</secondary_id>
    <nct_id>NCT00204321</nct_id>
  </id_info>
  <brief_title>Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients</brief_title>
  <official_title>Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients - Positive Effects of Calcineurin-free Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Else Kröner Fresenius Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <brief_summary>
    <textblock>
      Chronic transplant nephropathy and cardiovascular death are the main reasons for loss of
      transplanted organs after kidney transplantation.

      Vascular changes, induced by hypertension and/or immunological processes, determine long time
      transplant survival.

      It will be tested whether the withdrawal of calcineurininhibitors will improve the vessel
      wall function in renal transplant patients. It is supposed that this immunosuppressive
      regimen reduces the activation of endothelial cells with important impact on arteriosclerosis
      and therefore on patient and transplant survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular complications and chronic rejection are chief causes of transplant loss[1,2].
      After renal transplantation patients are still characterized by their pre-existing
      arteriosclerotic changes [3]. Endothelial dysfunction and disturbed distensibility of great
      arteries are independent predictors of cardiovascular morbidity [4,5]. Additionally the
      activation of sympathetic nervous system leads to dysfunction of vessel wall[6,7]. There are
      important therapeutic options in improvement of endothelial function [8].

      In addition monocytes of the recipient will contribute to vessel wall changes. [9-11]. Aim of
      therapy - especially of immunosuppressive therapy- have to prevent these fatal vessel wall
      changes.

      Therefore in this study the following topics will be addressed.

      1. Discontinuing of calcineurininhibitors will lead to improvement of vessel wall function 2.
      Sirolimus and Mycophenolat Mofetil affect vessel wall properties in a different way.

      3. There are risk factors, e.g. activity of sympathetic nervous system, which may determine
      the efficacy of discontinuing the calcineurininhibitor concerning the vessel wall function.

      4. Calcineurininhibitorfree immunosuppression reduces the activity of endothelial cells.

      5. Survival of monocytes and release of procoagulatory activity will be changed by the
      immunosuppressive regimen.

        1. Rostand SG, Brunzell JD, Cannon RO, Victor RG. Cardiovascular complications in renal
           failure. J Am Soc Nephrol. 1991; 2: 1053-1062

        2. London GM, Druecke TB. Atherosclerosis and arteriosclerosis in chronic renal failure.
           Kidney Int 1997; 51(6):1678-1695.

        3. Hausberg, M., K. Kisters, M. Kosch, K. H. Rahn, and M. Barenbrock. Flow-mediated
           vasodilation and distensibility of the brachial artery in renal allograft recipients.
           Kidney Int. 55: 1104-1110, 1999.

        4. Barenbrock M, Kosch M, Jöster E, Kisters K, Rahn KH, Hausberg M: Reduced arterial
           distensibility is a predictor of cardiovascular disease in patients after renal
           transplantation. Journal of Hypertension 2002, 20:79-84.

        5. London GM, Pannier B, Agharazii M, Guerin AP, Verbeke FHM, Marchais SY. Forearm reactive
           hyperemia and mortality in end-stage-disease. Kidney Int 2004, 65:700-704.

        6. Converse RL, Jacobsen TN, Toto RD, Jost CMT, Cosentino F, Fouad-Tarazi F, Victor RG.
           Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;
           327:1912-1918.

        7. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH.
           Sympathetic nerve activity in end-stage renal disease. Circulation. 2002, 106:1974-9.

        8. Kosch M, Barenbrock M, Kisters K, Rahn KH, Hausberg M. Relationship between muscle
           sympathetic nerve activity and large artery mechanical vessel wall properties in renal
           transplant patients. J Hypertens. 2002, 20:501-8.

        9. Österud, A., Björklid E. Role of monocytes in atherogenesis. Physiological reviews,
           2003, 83: 1069-1112.

       10. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan
           14;340(2):115-26.

       11. Lessner SM, Prado HL, Waller EK, Galis ZS. Atherosclerotic lesions grow through
           recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol.
           2002 Jun;160(6):2145-55.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>distensibility</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>sympathetic nervous system activity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>endothelial cell marker expression</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>monocyte survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Renal Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus (drug), mmf (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        renal transplantation stable function

        Exclusion Criteria:

        acute rejection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Hausberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKM - Medical Department D</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UKM</name>
      <address>
        <city>Münster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>January 12, 2010</last_update_submitted>
  <last_update_submitted_qc>January 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Hausberg</name_title>
    <organization>UKM</organization>
  </responsible_party>
  <keyword>rejection</keyword>
  <keyword>vesselwall function</keyword>
  <keyword>endothelial cell function</keyword>
  <keyword>monocytes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

